User profiles for Jenny Y. Chien

Jenny Y Chien

Eli Lilly and Company
Verified email at lilly.com
Cited by 3775

[PDF][PDF] The effects of LY2405319, an FGF21 analog, in obese human subjects with type 2 diabetes

G Gaich, JY Chien, H Fu, LC Glass, MA Deeg… - Cell metabolism, 2013 - cell.com
Fibroblast growth factor 21 (FGF21) is a recently discovered metabolic regulator. Exogenous
FGF21 produces beneficial metabolic effects in animal models; however, the translation of …

CYP2E1 activity before and after weight loss in morbidly obese subjects with nonalcoholic fatty liver disease

MG Emery, JM Fisher, JY Chien, ED Kharasch… - Hepatology, 2003 - Elsevier
Previous studies suggest that hepatic cytochrome P450 2E1 (CYP2E1) activity is increased
in individuals with chronic alcoholism, nonalcoholic steatohepatitis (NASH), and morbid …

PHRMA CPCDC initiative on predictive models of human pharmacokinetics, part 5: Prediction of plasma concentration–time profiles in human by using the …

…, HM Jones, CR Gibson, M Rowland, JY Chien… - Journal of …, 2011 - Elsevier
The objective of this study is to assess the effectiveness of physiologically based
pharmacokinetic (PBPK) models for simulating human plasma concentration–time profiles for the …

PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 3: comparative assessement of prediction methods of human clearance

BJ Ring, JY Chien, KK Adkison… - Journal of …, 2011 - Wiley Online Library
The objective of this study was to evaluate the performance of various allometric and in vitro–in
vivo extrapolation (IVIVE) methodologies with and without plasma protein binding …

Pharmacokinetics/pharmacodynamics and the stages of drug development: role of modeling and simulation

JY Chien, S Friedrich, MA Heathman, DP de Alwis… - The AAPS journal, 2005 - Springer
Pharmacokinetic (PK) and pharmacodynamic (PD) modeling and simulation (M&S) are well-recognized
powerful tools that enable effective implementation of the learn-and-confirm …

PhRMA CPCDC initiative on predictive models of human pharmacokinetics, part 2: comparative assessment of prediction methods of human volume of distribution

…, M Rowland, CR Gibson, JWT Yates, JY Chien… - Journal of …, 2011 - Elsevier
The objective of this study was to evaluate the performance of various empirical, semimechanistic
and mechanistic methodologies with and without protein binding corrections for the …

Ethanol and production of the hepatotoxic metabolite of acetaminophen in healthy adults

…, JT Slattery, H Ro, JY Chien… - Clinical …, 2000 - Wiley Online Library
Background Recent case reports suggest that consumption of ethanol may increase the risk
of liver injury induced by acetaminophen (INN, paracetamol). However, this possibility is at …

Clinical pharmacokinetics of dulaglutide in patients with type 2 diabetes: analyses of data from clinical trials

…, X Cui, J Martin, C Loghin, JY Chien… - Clinical …, 2016 - Springer
Background and Objective Dulaglutide is a long-acting glucagon-like peptide-1 receptor
agonist administered as once-weekly subcutaneous injections for the treatment of type 2 …

A quantitative modeling and simulation framework to support candidate and dose selection of anti‐SARS‐CoV‐2 monoclonal antibodies to advance bamlanivimab …

…, A Elmokadem, T Knab, JY Chien - Clinical …, 2022 - Wiley Online Library
Neutralizing monoclonal antibodies (mAb), novel therapeutics for the treatment of coronavirus
disease 2019 (COVID‐19) caused by severe acute respiratory syndrome‐coronavirus 2 (…

Age-dependent tetrahydrothiophenium ion formation in young children and adults receiving high-dose busulfan

JP Gibbs, G Murray, L Risler, JY Chien, R Dev… - Cancer research, 1997 - AACR
Busulfan, a bifunctional alkylating agent, is a mainstay of myeloablative preparative regimens
before hematopoietic stem cell transplantation. The apparent oral clearance of busulfan …